Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 randomized, multi-center, double-blind, placebo-controlled, parallel-group, multiple dose safety and efficacy study of epinastine nasal spray vs. placebo in subjects with seasonal allergic rhinitis.

Next Previous
X
Search
Trial Profile

A phase 3 randomized, multi-center, double-blind, placebo-controlled, parallel-group, multiple dose safety and efficacy study of epinastine nasal spray vs. placebo in subjects with seasonal allergic rhinitis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epinastine (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 20 May 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 23 Apr 2008 Status changed from in progress to discontinued, as reported by Inspire Pharmaceuticals in a company media release.
    • 23 Apr 2008 Inspire Pharmaceuticals reported in a media release that this trial failed to meet it's primary endpoint. Subsequently development of epinastine nasal spray is to be discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top